The stunning success of CAR T therapy over the past couple years has spawned a new industry and a proliferation of CAR, TCR and TIL constructs. Engineering efforts are aimed at improving the design, targeting, developability, manufacturing, and scalability of new formats to solve issues that remain, including improving the safety of immunotherapy, affordability and targeting of solid tumors. The tumor microenvironment and the microbiome are being tapped to predict the efficacy of immunotherapy and optimize results.


Coverage will include, but is not limited to:


  • Developing T-cell therapies against emerging indications including autoimmune disorders
  • Proliferating allogeneic therapy in hematological and solid tumors
  • Applying gene editing and CRISPR to immunotherapy design
  • Interrogating and targeting key players in the tumor microenvironment
  • Evaluating how the microbiome can be used to predict immunotherapy success
  • Optimizing manufacturability and scale-up
  • Striking a balance between toxicity and efficacy
  • Selecting combinations of immunotherapies
  • Reviewing recent successes and failures in adoptive T cell therapy
  • Overcoming resistance to therapy with novel strategies

* The program is subject to change without notice, due to unforeseen reason.